You are here: Industry Insights > AbbVie

News List

AbbVie licenses GARP checkpoint inhibitor from Argenx fiercebiotech
August 23, 2018
AbbVie has taken up its option to license an immune checkpoint inhibitor from Argenx. The dealgives AbbVie the global rights to an anti-GARP antibody designed to block the immunosuppressive activity of regulatory T cells (Tregs).
Tolero Pharmaceuticals and AbbVie partner to develop AML therapy pharmaceutical
August 22, 2018
Biopharmaceutical firm Tolero Pharmaceuticals and AbbVie have formed a clinical research alliance to evaluate venetoclax and alvocidib combination for relapsed or refractory acute myeloid leukaemia (AML) treatment.
Tolero Pharmaceuticals collaborates with AbbVie for AML trial biospectrumasia
August 21, 2018
Under the terms of the agreement, Tolero and AbbVie will equally share all development expenses. Tolero will retain full commercial rights for alvocidib and AbbVie will retain full commercial rights for venetoclax.
Tolero Pharmaceuticals, AbbVie Announces Clinical Research Collaboration americanpharmaceuticalreview
August 20, 2018
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie exploring the potential of combination therapy with AbbVie's venetoclax and Tolero's investigational agent, alvocidib, for the treatment of relapsed/refractory acute mye
AbbVie, Tolero team up to test Venclexta combo in AML fiercebiotech
August 20, 2018
Tolero Pharmaceuticals has inked a pact to test its CDK9 inhibitor, alvocidib, in combination with AbbVie’s BCL-2 blocker Venclexta in relapsed/refractory acute myeloid leukemia (AML). The pair will equally share development costs.
AbbVie surprised investors with its hepatitis C success. Will it last? biopharmadive
August 13, 2018
By the time AbbVie brought its first drug for hepatitis C to market, in December 2014, it was already too late.
Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer and more fiercepharma
August 08, 2018
It’s that time of year again—the time when lead PBM Express Scripts ignites pharma’s ire with a brand-new list (PDF) of formulary exclusions.
Hop on the bus: AbbVie takes hepatitis C testing to veterans in co-campaign with American Legion fiercepharma
August 02, 2018
With its new hepatitis C drug already on a roll, AbbVie is hitting the road this month to spur veterans toward hepatitis C testing in a cross-country bus tour with the American Legion. The idea? Testing is the only way to find patients needing treatment.
As Humira competition nears, AbbVie's Imbruvica and Mavyret pick up steam fiercepharma
July 30, 2018
Even as AbbVie's megablockbuster immunology med Humira inches toward its first biosim competition, the drug is still churning out record sales.
US approves AbbVie/Neurocrine’s uterine pain drug pharmatimes
July 26, 2018
AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page